Latest IR Information

Financial Highlights | 2nd Quarter of Fiscal 2026

Second quarter of the fiscal year ending March 31, 2027 (April 1, 2026 to September 30, 2026) | Announced October 29, 2026
 

For the first half (interim period) of fiscal 2026, consolidated revenue was 350.4 billion yen (up 64.5% year on year), operating profit was 115.2 billion yen (up 55.8%) and profit attributable to owners of parent was 119.5 billion yen (up 44.0%). Revenue growth was driven mainly by an increase in royalty income centered on the HIV franchise, growth in Torii Pharmaceutical-related products and the insomnia treatment QUVIVIQ, and the expansion of our overseas business following the succession to the edaravone business.

Reflecting the steady progress of our core businesses, we have revised upward our full-year forecast for FY2026 to revenue of 720.0 billion yen (up 20.0 billion yen from the previous forecast), operating profit of 230.0 billion yen (up 10.0 billion yen) and profit attributable to owners of parent of 212.5 billion yen (up 2.5 billion yen).Overseas, we expect sales to grow through the RADICAVA business and, upon completion of the acquisition of IntraBio Inc., the launch of AQNEURSA, a treatment for Niemann-Pick disease type C (NPC) and ataxia-telangiectasia (A-T). In Japan, we expect further market penetration of QUVIVIQ, and in the HIV business, we expect increases in royalty income and share of profit of investments accounted for using the equity method, supported by the strong performance of ViiV Healthcare. On the cost side, amortization of intangible assets related to the acquisition of IntraBio is expected to increase, while we will continue to prioritize and focus our R&D investments.

  Revenue Operating profit Profit attributable to owners of parent
Results 350.4 B yen 115.2 B yen 119.5 B yen
Y o Y +64.5% +55.8% +44.0%

2Q Financial Results & Supplement

2Q Presentation materials